Tuesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adults with pulmonary arterial hypertension to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events.
Cantor Fitzgerald writes that the label was better than anticipated. There is no Black Box, no Risk Evaluation and Mitigation Strategy (REMS), and only initial monitoring.
Cantor analyst writes that Merck’s stock has shown robust performance year-to-date, with a gain of approximately 15% compared to the S&P 500’s 10% increase.
This upward trend began towards the end of the previous year. While some investors may consider reducing their holdings in Merck, Cantor analyst says it’s premature to do so, especially ...